This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr.Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. In this episode we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions. 01:43 Meet Stanley Qi03:32 Founding Epicrispr05:53 CRISPR interference and epigenome explained10:04 Overview of GEMS gene modulation system11:28 Reversibility and safety of epigenetic edits18:42 Strategy for tackling multiple disease conditions23:27 Clinical trial plans for EPI-321 candidate30:06 Looking forwardThis episode is brought to you with the support of MedChemExpress.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Could CRISPR really cure these diseases?10 gene therapy companies you should know aboutCRISPR technology’s next wave: Ten companies to watch